Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,
Updated on: January 04,2024
8
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,
Updated on:January 04,2024
8